Lung cancer

Cancer research

Prioritizing Bevacizumab Plus Chemotherapy in PD-L1-Negative Lung Adenocarcinoma Patients

Research conducted at the Affiliated Cancer Hospital of Zhengzhou University has highlighted the effectiveness of bevacizumab plus chemotherapy as a first-line treatment option for programmed death-ligand 1 (PD-L1) negative lung adenocarcinoma (LUAD) patients without common gene-alterations. The study, published in Frontiers in Oncology, analyzed the clinical effectiveness and safety of